CBSE schools must submit Class 9, 11 registration data for board exams 2025-26 by October 16, 2025. Schools must upload accurate student details and meet the stipulated deadline. The board has issued ...
Hosted on MSN
CBSE reminds schools to submit registration data for class 9 and 11 students by October 16: Check details here
The Central Board of Secondary Education (CBSE) has issued a fourth reminder to all affiliated schools regarding the submission of registration data for Class IX and Class XI for the academic year ...
Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...
March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS’’ or the 'Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...
Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F ...
CLN-049 achieved promising anti-leukemic activity in this heavily pretreated AML population: Anti-leukemic activity was observed at target doses =6 µg/kg (n=23, all AML), with a CRc rate of 30%, and ...
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-exp ...
The issue of attendance has become a focus for the district, which has been included in a pilot program with 11 other ...
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback